WST Quote, Financials, Valuation and Earnings

Merit Medical Systems has a net margin of 18.21% compared to West Pharmaceutical Services's net margin of 8.37%. West Pharmaceutical Services's return on equity of 18.16% beat Merit Medical Systems's return on equity of 9.56%.

West Pharmaceutical Services has a consensus price target of $378.17, signalling upside risk potential of 13.42%. On the other hand Merit Medical Systems has an analysts' consensus of $113.20 which suggests that it could grow by 14.99%. Given that Merit Medical Systems has higher upside potential than West Pharmaceutical Services, analysts believe Merit Medical Systems is more attractive than West Pharmaceutical Services.

West Pharmaceutical Services has a beta of 1.007, which suggesting that the stock is 0.671% more volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.844, suggesting its less volatile than the S&P 500 by 15.557%.

West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.24%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 9.61% of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

West Pharmaceutical Services quarterly revenues are $746.9M, which are larger than Merit Medical Systems quarterly revenues of $339.8M. West Pharmaceutical Services's net income of $136M is higher than Merit Medical Systems's net income of $28.4M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 49.47x while Merit Medical Systems's PE ratio is 48.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 8.58x versus 4.37x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Repligen has a net margin of 18.21% compared to West Pharmaceutical Services's net margin of -0.42%. West Pharmaceutical Services's return on equity of 18.16% beat Repligen's return on equity of -0.41%.

West Pharmaceutical Services has a consensus price target of $378.17, signalling upside risk potential of 13.42%. On the other hand Repligen has an analysts' consensus of $191.46 which suggests that it could grow by 31.34%. Given that Repligen has higher upside potential than West Pharmaceutical Services, analysts believe Repligen is more attractive than West Pharmaceutical Services.

West Pharmaceutical Services has a beta of 1.007, which suggesting that the stock is 0.671% more volatile than S&P 500. In comparison Repligen has a beta of 0.965, suggesting its less volatile than the S&P 500 by 3.502%.

West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.24%. Repligen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 9.61% of its earnings as a dividend. Repligen pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

West Pharmaceutical Services quarterly revenues are $746.9M, which are larger than Repligen quarterly revenues of $154.9M. West Pharmaceutical Services's net income of $136M is higher than Repligen's net income of -$654K. Notably, West Pharmaceutical Services's price-to-earnings ratio is 49.47x while Repligen's PE ratio is 628.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 8.58x versus 12.93x for Repligen. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of 18.21% compared to West Pharmaceutical Services's net margin of -4291.67%. West Pharmaceutical Services's return on equity of 18.16% beat Catheter Precision's return on equity of -65.84%.

West Pharmaceutical Services has a consensus price target of $378.17, signalling upside risk potential of 13.42%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 377.33%. Given that Catheter Precision has higher upside potential than West Pharmaceutical Services, analysts believe Catheter Precision is more attractive than West Pharmaceutical Services.

West Pharmaceutical Services has a beta of 1.007, which suggesting that the stock is 0.671% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.24%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 9.61% of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

West Pharmaceutical Services quarterly revenues are $746.9M, which are larger than Catheter Precision quarterly revenues of $96K. West Pharmaceutical Services's net income of $136M is higher than Catheter Precision's net income of -$4.1M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 49.47x while Catheter Precision's PE ratio is 0.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 8.58x versus 1.12x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of 18.21% compared to West Pharmaceutical Services's net margin of -17.98%. West Pharmaceutical Services's return on equity of 18.16% beat Xtant Medical Holdings's return on equity of -35.98%.

West Pharmaceutical Services has a consensus price target of $378.17, signalling upside risk potential of 13.42%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 418.19%. Given that Xtant Medical Holdings has higher upside potential than West Pharmaceutical Services, analysts believe Xtant Medical Holdings is more attractive than West Pharmaceutical Services.

West Pharmaceutical Services has a beta of 1.007, which suggesting that the stock is 0.671% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.24%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 9.61% of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

West Pharmaceutical Services quarterly revenues are $746.9M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. West Pharmaceutical Services's net income of $136M is higher than Xtant Medical Holdings's net income of -$5M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 49.47x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 8.58x versus 0.51x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.